Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Psychedelics have been recreational substances for decades. Now, they're entering the mainstream of psychiatric treatment.

Compass Pathways has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

The government is preparing to fund the use of MDMA and psylocibin, otherwise known as ecstasy and magic mushrooms, as a ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...